Celyad Oncology (CYAD) H1 2026 earnings summary

Executive summary

• Focus shifted to monetizing intellectual property after discontinuing R&D and clinical trials in 2022, with efforts to secure licensing or asset sale agreements.

• Sale of the C-CathEZ catheter business to CellProthera completed in February 2026, with up to €5 million in milestone-based payments and future royalties.

• Private placement of €0.5 million in July 2026 extended cash runway to mid Q2 2027.

Financial highlights

• Net loss for H1 2026 was €1.2 million, a significant improvement from €3.7 million in H1 2025.

• Operating loss for H1 2026 was €1.2 million, compared to €3.7 million in H1 2025.

• Cash and cash equivalents stood at €0.1 million as of June 30, 2026, down from €1.7 million at year-end 2025.

• Employee benefit expenses dropped to €0.4 million due to workforce reduction.

• Other income increased due to gain on sale of the C-Cath business.

Outlook and guidance

• Cash runway extended to mid Q2 2027 following the July 2026 private placement.

• Additional funding required by mid Q2 2027; company is evaluating financing options including equity, debt, partnerships, or asset sales.

• No assurance of securing further financing, indicating material uncertainty about going concern status.